Cargando…
Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data
INTRODUCTION: The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study showed that compared with placebo, canagliflozin 100 mg significantly reduced the risk of major cardiovascular events and adverse renal outcomes in patients with diabetic...
Autores principales: | Willis, Michael, Asseburg, Christian, Slee, April, Nilsson, Andreas, Neslusan, Cheryl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547928/ https://www.ncbi.nlm.nih.gov/pubmed/32930969 http://dx.doi.org/10.1007/s13300-020-00923-w |
Ejemplares similares
-
Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review
por: Willis, Michael, et al.
Publicado: (2019) -
Of credence and credibility: A year gone by
por: Jain, Sanjay N
Publicado: (2014) -
Commentary: Religious credence is not factual belief
por: Talmont-Kaminski, Konrad
Publicado: (2016) -
CREDENCE: A silver lining in the dark cloud of diabetic nephropathy
por: Hanai, Ko, et al.
Publicado: (2019) -
Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
por: Mohebi, Reza, et al.
Publicado: (2023)